The 15 most recent market catalysts affecting $VCYT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 65
Stephens & Co. Maintains Overweight Rating on Veracyte
Stephens & Co. analyst Mason Carrico maintained an 'Overweight' rating on Veracyte, which is generally a positive signal for the stock. However, the simultaneous reduction of the p…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 65
UBS Adjusts Price Target on Veracyte to $35 From $65, Maintains Buy Rating
UBS has adjusted its price target for Veracyte (VCYT) from $65 down to $35, a substantial cut, yet it has maintained a 'Buy' rating. This indicates that while UBS still sees long-t…
Nov 6, 2026
Corporate Catalyst
Bearish
Impact 85
Shareholder Investigation Initiated into Veracyte, Inc. Following Stock Decline
Veracyte announced a significant miss on Decipher Prostate test volumes and subsequently lowered its 2026 revenue guidance. This news caused a substantial drop in the company's sto…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 80
Veracyte Announces $100 Million Share Buyback Program and Narrows 2026 Revenue Outlook
Veracyte announced a $100 million share buyback program, which often signals management's confidence and can support share price. However, this positive news is tempered by a downw…
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 65
Leerink Partners Downgrades Veracyte to Market Perform
Leerink Partners downgraded Veracyte, Inc. from 'Outperform' to 'Market Perform' and assigned a $35 price target. This action signals a reduced confidence in the company's near-ter…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 85
Veracyte, Inc. Reports Financial Results for the Third Quarter 2026
Veracyte, Inc. announced its third-quarter 2026 financial results, revealing a nuanced performance. While the Afirma test exceeded internal projections, the Decipher Prostate test …
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
Veracyte Announces New Data for Decipher Prostate Genomic Classifier
Veracyte announced new data from a retrospective analysis of the STAMPEDE trial, indicating its Decipher Prostate Genomic Classifier can predict which very high-risk prostate cance…
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 75
Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program
Veracyte announced that its Prosigna Breast Risk of Recurrence test has secured coverage through Palmetto GBA’s MolDX program, effective August 19, 2026. This is a crucial developm…
Sep 29, 2026
Corporate Catalyst
Neutral
Impact 65
Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting
Veracyte announced that its Decipher Prostate Genomic Classifier has shown new predictive capabilities in a retrospective analysis of a Phase III trial. The study found that patien…
Sep 9, 2026
Market Technicals
Bullish
Impact 55
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel has maintained a 'Buy' rating on Veracyte and raised the price target from $52 to $65. This upgrade signals increased confidence from a major financial in…
Aug 19, 2026
Market Technicals
Bearish
Impact 55
Top 3 Health Care Stocks That Could Blast Off This Month
The filing identifies Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN) as oversold healthcare stocks, each with an RSI below 30. This technical indicator suggest…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 55
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
Morgan Stanley analyst Tejas Savant maintained an 'Underweight' rating on Veracyte and lowered the price target from $47 to $44. This action indicates a continued bearish sentiment…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Veracyte, Raises Price Target to $69
Needham analyst Mike Matson maintained a 'Buy' rating on Veracyte and raised the price target from $57 to $69. This action signals increased confidence from a prominent analyst in …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est
Veracyte (VCYT) announced an upward revision to its fiscal year 2026 sales guidance, moving from a range of $582.000 million-$592.000 million to $590.000 million-$596.000 million. …
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 65
Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66
Piper Sandler analyst David Westenberg has initiated coverage on Veracyte (VCYT) with an Overweight rating and a $66 price target. This is a significant event for VCYT as new analy…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.